# Safety and Tolerability of Oral CM082 in Patients With wAMD

> **NCT03710863** · PHASE2 · UNKNOWN · sponsor: **AnewPharma** · enrollment: 64 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** CM082

## Key facts

- **NCT ID:** NCT03710863
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-22
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710863, "Safety and Tolerability of Oral CM082 in Patients With wAMD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03710863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*